SpringWorks Therapeutics is showing promising growth with its first approved drug and a potential second approval for mirdametinib in NF1 treatment. Despite a net loss of $53.5 million in Q3 2024, the company has strong cash reserves and growing sales. Key strengths include sustained sales growth and potential drug approvals, while risks involve market competition and aggressive goal setting.